Baseline severity of sepsis in subjects of the prowess and the kybersept clinical trials on endogenous anticoagulants

Shock

Volumn 25, Issue 6, 2006, Pages 657-658

  Wiedermann, Christian J ^a,e   Keinecke, Heinz Otto ^b   Jürs, Mathias ^c   Opal, Steve M ^d  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

^b ACCOVION GMBH   (Germany)

^c ZLB Behring GmbH   (Germany)

^d RHODE ISLAND HOSPITAL   (United States)

^e Central Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; DROTRECOGIN; PROTEIN C; RECOMBINANT PROTEIN;

ARTICLE; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; MORTALITY; SEPSIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HOSPITALIZATION; MALE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ANTICOAGULANTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 33745610509     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000223305.35238.0c     Document Type: Article

References (7)

1. Freemann BD, Zehnbauer BA, Buchman TG: A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 20:5-9, 2003.
2. Iba T, Kidokoro A: What can we learn from the three megatrials using anticoagulants in severe sepsis? Shock 22:508-512, 2004.
3. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM: High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 34:285-292, 2006.
4. Haley M, Cui X, Minneci PC, Deans KJ, Natanson C, Eichacker PQ: Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness. Curr Opin Infect Dis 17:205-211, 2004.
5. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR: for the PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31:12-19, 2003.
6. LeGall JR, Lemeshow S, Leleu G, Klar J, Huillard J, Rue M, Teres D, Artigas A: Customized probability models for early severe sepsis in adult intensive care patients. Intensive Care Unit Scoring Group. JAMA 273: 644-650, 1995.
7. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossalnt R, Perrotin D, Sablotzki A, Arkins N, Uttorback BG, Maclas WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group: Drotrecogin alfa (Activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332-1341, 2005.